Bio-Rad Laboratories, Inc.
245 Linus Pauling Dr. Suite F
Hercules
California
94521
United States
602 articles about Bio-Rad Laboratories, Inc.
-
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
4/18/2024
Bio-Rad Laboratories, Inc. will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market.
-
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
4/11/2024
Oncocyte Corporation, a precision diagnostics company, announced a partnership agreement with Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, for the commercialization of its research use only GraftAssure™ assay, powered by Droplet Digital™ PCR *.
-
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
4/10/2024
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024.
-
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
3/20/2024
Bio-Rad Laboratories, Inc. today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024.
-
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
2/22/2024
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time).
-
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
2/15/2024
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
1/24/2024
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market.
-
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference
1/2/2024
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced that Norman Schwartz, President and CEO, and Andrew Last, Executive Vice President and COO, will host one-on-one meetings with investors during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, January 8 - 11, 2024.
-
Bio-Rad Reports Third-Quarter 2023 Financial Results
10/26/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.
-
Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023
10/5/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market.
-
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference
8/28/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).
-
Bio-Rad Reports Second-Quarter 2023 Financial Results
8/3/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023.
-
Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
7/26/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
-
Bio-Rad Announces New Share Repurchase Program - July 20, 2023
7/20/2023
Bio-Rad Laboratories, Inc. announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.
-
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
7/10/2023
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market.
-
Bio-Rad Publishes Corporate Sustainability Report for 2022
7/10/2023
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, released its corporate sustainability report for fiscal year ended December 31, 2022.
-
Bio-Rad to Present Company Overview at Jefferies Healthcare Conference
6/1/2023
Bio-Rad Laboratories, Inc. today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time.
-
Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference
5/8/2023
Bio-Rad Laboratories, Inc. today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).
-
Bio-Rad Reports First-Quarter 2023 Financial Results
5/4/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023.
-
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
4/12/2023
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market.